pharmaphorum

SEPTEMBER 5, 2022

Sam Crowther, founder and CEO of cybersecurity company Kasada, tells us about a recent discovery his company made that revealed tens of thousands of accounts with prescription drug attachments in major online pharmacies had been compromised. While performing analysis for a client of online accounts for sale, Kasada uncovered a new and illegal way bots are being used – to steal pharmacy customers’ accounts and resell prescriptions on a secondary market for in-demand substances, such as Oxyc

Compounding 138

Compounding Controlled Substances 138

STAT

SEPTEMBER 5, 2022

By this time next year, if the medical forecasts are correct, I will probably be dead, another casualty of a fatal illness that most people have never heard of: idiopathic pulmonary fibrosis (IPF). This condition has been described by Michael J. Stephen in his 2021 book “Breath Taking” as the “most frustrating and disheartening of all the diseases in pulmonary medicine.

137

137

Pharmacy Times

SEPTEMBER 5, 2022

Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses why pharmacy technicians are leaving the profession and why they are staying.

PTCB 123

PTCB 123

Drug Topics

SEPTEMBER 5, 2022

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

98

98

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

SEPTEMBER 5, 2022

Following AstraZeneca’s success in vaccine development during the Covid-19 pandemic , the pharmaceutical giant is now looking to expand its scope through acquisitions across a range of indications, says CEO Pascal Soriot. “We want to be a sustainably growing company. Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”.

FDA 114

FDA Vaccines 114

Drug Topics

SEPTEMBER 5, 2022

In a recent study, children were successfully able to self-swab and receive their own COVID-19 test results after basic instructions.

98

98

Omnicell

SEPTEMBER 5, 2022

Lani Bertrand, RPh Senior Director, Clinical Consulting, Omnicell Ask any pharmacy professional who works with a pharmacy platform comprised of disparate, disconnected systems, and they’ll tell you this: when systems aren’t interoperable, problems, such as incomplete and incorrect medication data, sub-optimal inventory management, drug shortages, and ever-present diversion risks — to name but a few, start snowballing fast.

Controlled Substances 98

Controlled Substances Omnicell Patient Care Hospitals 98

pharmaphorum

SEPTEMBER 5, 2022

Greater use of telehealth services forced by COVID-19 seems to have benefitted people with opioid use disorder (OUD), leading to longer times on treatment and reduced risk of overdose, according to a new study. The researchers examined data from two groups of Medicare patients, one treated for OUD before the pandemic, and another who were treated after COVID-19 took hold, with greater use of telehealth support to complement in-person care.

98

98

Pharmacy Times

SEPTEMBER 5, 2022

Students from the Daniel K. Inouye College of Pharmacy discuss their experience at the University of Hawaii.

121

121

pharmaphorum

SEPTEMBER 5, 2022

Shares in PolyPid have been under pressure after the Israeli biotech reported its antibiotic for surgical site infections failed a phase 3 trial, although there may still be a way forward for the programme. The SHIELD I trial of D-PLEX 100 – a new formulation of the well-established antibiotic doxycycline – found that giving the drug wasn’t able to improve on regular care in preventing infections in people undergoing abdominal surgery.

Hospitals 78

Hospitals FDA 78

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

SEPTEMBER 5, 2022

Factors such as increasing access to health information, the introduction of new medical treatments and technologies and the spike in birth rate are increasing the need for payers in the pharmaceutical industry. Payers ensure the delivery of the best possible health outcomes to the patients from their financial plan. Finding the top payers in the pharmaceutical industry.

Documentation 59

Documentation Hospitals 59

pharmaphorum

SEPTEMBER 5, 2022

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance Pharma, from serving as a company director. Butterfield is one of seven company directors from Alliance, Lexon, Focus Pharma, and Medreich in the financial regulator’s sights, in connection with allegations that they colluded to raise the NHS price of widely-used nausea drug prochlorperazine, raking in millions of pounds in excess profits.

59

59

Pharmaceutical Technology

SEPTEMBER 5, 2022

Pharmaceutical companies hold permission to market their products directly to consumers. The direct-to-consumer marketing companies for pharmaceuticals are increasingly moving online as it supports the digitisation of information, enabling patients to take control of their health. Pharmaceutical companies have also entered the social media marketing domain in compliance with governmental regulations to communicate directly with patients using covert persuasion methods such as collaboration with

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication Documentation 52

Omnicell

SEPTEMBER 5, 2022

Jeff Spencer Senior Director, Sales and Account Management, Omnicell For more than 25 years, the 340B Drug Pricing Program has provided financial assistance to eligible hospitals and other healthcare facilities serving vulnerable communities. The program allows 340B covered entities to stretch limited federal resources and expand health services to the patients and communities they serve.

Omnicell 52

Omnicell Hospitals 52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

SEPTEMBER 5, 2022

Pharmaceutical wholesalers act as intermediaries between pharmaceutical manufacturers and retailers and facilitate the delivery of the right medicines in a timely, efficient, and secure manner. Wholesale distributors are responsible for guaranteeing product quality and preventing the influx of counterfeited drugs. Wholesalers can be either full-line wholesalers, who purchase the complete product line of a company, or specialised companies, which purchase speciality drugs to sell to clinics and h

Documentation 52

Documentation Packaging Labelling Pharmaceutical Companies 52

Omnicell

SEPTEMBER 5, 2022

Joy Somogyi Senior Director, Product Marketing, Omnicell With exponential growth in development of novel treatments , the scope of a health system’s formulary, and the associated data, continues to expand year over year. Coupled with inventory management challenges including $800 million lost due to expired medications and the $454 million impact of clinical drug diversion , pharmacy needs to gain better understanding of how cloud computing and big data can improve the supply chain.

Omnicell 52

Omnicell Medical Records Hospitals 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

The US Food and Drug Administration (FDA) has approved the expanded usage of Vertex Pharmaceuticals ’ Orkambi (lumacaftor/ivacaftor) to treat cystic fibrosis (CF) in children aged 12 months to under 24 months. The treatment is indicated for CF patients who are homozygous for the F508del mutation (F/F genotype) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

FDA 52

FDA Labelling 52

Omnicell

SEPTEMBER 5, 2022

Neil DiBernardo, PharmD, Omnicell Solution Design Pharmacist Consultant The benefits of a fully autonomous pharmacy are widely recognized – reduced medication errors, less waste, improved efficiencies, more opportunity to focus on higher-value patient care. Yet many pharmacies are still putting off the adoption of autonomous solutions. Why? Often, the need to change is eclipsed by the fear and complexity of change.

Patient Care 52

Patient Care Omnicell Hospitals 52

PioneerRx

SEPTEMBER 5, 2022

There are so many things that go into an independent pharmacy’s success: the quality of patient care, the range (or lack) of clinical services you provide, the.

Independent Pharmacies 52

Independent Pharmacies Patient Care 52

Omnicell

SEPTEMBER 5, 2022

Ken Osborn Senior Director, Product Marketing, Omnicell Latest Innovation in Winter 2020 Release Advances Journey to the Autonomous Pharmacy The need for solutions designed to help customers achieve greater visibility, control costs, and better manage an increasingly complex pharmacy supply chain is more important than ever. Omnicell’s Winter 2020 release features new functionality for automation, enhanced intelligence, and technology-enabled services designed to simplify workflows, provid

Omnicell 52

Omnicell Controlled Substances Hospitals Patient Care 52

Pharma Times

SEPTEMBER 5, 2022

Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data

46

46

Omnicell

SEPTEMBER 5, 2022

Alison Curran Senior Manager of Professional Services, Omnicell One of the biggest failure points in a pharmacy technology implementation stems from lack of communication and alignment. Often, the goal and outcomes of the project are not effectively communicated across the organization, resulting in each stakeholder having a different definition of what constitutes success.

Communication 52

Communication Omnicell Hospitals 52

Pharma Times

SEPTEMBER 5, 2022

Warning comes from NHS leaders as new Prime Minister prepares to move into Number 10

45

45

Omnicell

SEPTEMBER 5, 2022

Mark Neuenschwander Founding Director, THRIVCoalition.org Seminal research from 1997 on IV compounding discovered that 9 percent of manually compounded sterile preparations had incorrect ingredients and/or volumes. While a study from two decades ago may no longer seem relevant, the fact is, the vast majority of today’s IVs are still being prepared through error-prone manual processes.

Compounding 52

Compounding Sterile Compounds Compounding Pharmacies Documentation 52

Hospital Pharmacy Europe

SEPTEMBER 5, 2022

Roberta di Blasi MD PhD is a haematologist at Saint Louis Hospital in Paris where she is a specialist in CAR-T cell therapy for lymphoma. Here she shares her thoughts and perceptions on CAR-T therapy and its role in treating patients with lymphomas. Please tell us a little about yourself and your institution? Prior to her appointment in Paris, Dr di Blasi completed her residency in haematology at the Catholic University School of Medicine, Policlinico Universitario Agostino Gemelli in Rome.

Hospitals 52

Hospitals Chemotherapy Immunization 52

Omnicell

SEPTEMBER 5, 2022

Tanja Portmann Vice President of Professional Services Omnicell As health systems continue to adopt new technologies and digital transformations, it often causes a dramatic shift that can be jolting and confusing for staff. According to a study by the IT research firm, The Standish Group, only 29 percent of healthcare IT projects are considered to be successful.

Omnicell 52

Omnicell Communication 52

Pharmaceutical Technology

SEPTEMBER 5, 2022

The National Medical Products Administration of China (NMPA) has approved CanSino Biologics ’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster. This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version. Providing a non-invasive option, Convidecia Air utilises a nebuliser to convert liquid into an aerosol for inhaling through the mouth, the company noted.

Vaccines 105

Vaccines Immunization 105

Omnicell

SEPTEMBER 5, 2022

Carol Kimura VP, Brand, Digital and Growth Marketing, Omnicell A year ago, we couldn’t have imagined the trials 2020 would bring to healthcare, yet health system pharmacists have risen to the challenge. From standing up temporary care areas, adding new treatment options to formularies, and navigating a strained inventory supply chain, we’ve seen the critical role of the pharmacist elevated throughout this pandemic.

Omnicell 52

Omnicell Patient Care 52

European Pharmaceutical Review

SEPTEMBER 5, 2022

Researchers have developed a self-optimising flow reactor platform for complex reactions. Based on rapid nuclear magnetic resonance (NMR) and Fourier-transform infrared spectroscopy (FTIR) spectroscopic measurements and processed using chemometric models, the platform was able to provide optimal reaction parameters with minimal background knowledge.

89

89

Omnicell

SEPTEMBER 5, 2022

Nhat H. Ngo EVP, Marketing, Strategy, and Business Development at Omnicell As more pharmacies and health systems embrace digital transformation, they now have access to powerful data sets that reveal patterns and trends that will allow them to better manage a complex medication supply chain. Visibility into and management of big data is leading to improved clinical, operational, and financial incomes in three key areas.

Omnicell 52

Omnicell Hospitals 52

pharmaphorum

SEPTEMBER 5, 2022

AstraZeneca’s checkpoint inhibitor Imfinzi has become the first immunotherapy to be approved by the FDA for biliary tract cancer (BTC), a rare and aggressive form of cancer with limited treatment options. Imfinzi (durvalumab) has been cleared by the US regulator for the treatment of adult patients with locally advanced or metastatic BTC in combination with gemcitabine/cisplatin chemotherapy, extending the use of Imfinzi beyond lung cancer for the first time.

FDA 52

FDA Chemotherapy Hospitals 52

Omnicell

SEPTEMBER 5, 2022

Dennis Wright, Sr. Director Central Pharmacy Product Marketing at Omnicell In many other industries we’ve seen success in how technology is accelerating and transforming the way products and services are created, delivered, consumed, and measured. Despite the pace of change elsewhere, health system pharmacy continues to lag in investing in and implementing transformational technology.

Omnicell 52

Omnicell Patient Care 52

Hospital Pharmacy Europe

SEPTEMBER 5, 2022

Autoimmune thyroiditis in children with thyroid nodules has been found to be independently linked to an increased risk of thyroid cancer. Children with autoimmune thyroiditis and thyroid nodules is independently associated with a higher risk of thyroid cancer according to the findings of a cross-sectional study by US researchers based at Harvard Medical School, US.

Medical Schools 52

Medical Schools Hospitals 52

Omnicell

SEPTEMBER 5, 2022

Jennifer Tryon, PharmD, MS, FASHP Associate Vice President and Chief Pharmacy Officer, Wake Forest Baptist Health Every day, the healthcare industry faces new challenges that are impeding goals to deliver quality patient care. The stress of managing more complex systems in the face of higher expectations continues to grow. In fact, a recent study from the National Academy of Medicine reports that 54% of clinicians are reporting some level of burn out.

Omnicell 52

Omnicell Patient Care Hospitals Compounding 52